Presentation in the framework of the International Conference "10th anniversary of the Spanish Network of Health Technology Assessment Agencies. Towads patient and public engagement in HTA" Zaragoza 27-28 April 2017
Presentation in the framework of the International Conference "10th anniversary of the Spanish Network of Health Technology Assessment Agencies. Towads patient and public engagement in HTA" Zaragoza 27-28 April 2017
Presentation in the framework of the International Conference "10th anniversary of the Spanish Network of Health Technology Assessment Agencies. Towads patient and public engagement in HTA" Zaragoza 27-28 April 2017
Presentation in the framework of the International Conference "10th anniversary of the Spanish Network of Health Technology Assessment Agencies. Towads patient and public engagement in HTA" Zaragoza 27-28 April 2017
Presentation in the framework of the International Conference "10th anniversary of the Spanish Network of Health Technology Assessment Agencies. Towads patient and public engagement in HTA" Zaragoza 27-28 April 2017
Presentation in the framework of the International Conference "10th anniversary of the Spanish Network of Health Technology Assessment Agencies. Towads patient and public engagement in HTA" Zaragoza 27-28 April 2017
Presentation in the framework of the International Conference "10th anniversary of the Spanish Network of Health Technology Assessment Agencies. Towads patient and public engagement in HTA" Zaragoza 27-28 April 2017
Presentation in the framework of the International Conference "10th anniversary of the Spanish Network of Health Technology Assessment Agencies. Towads patient and public engagement in HTA" Zaragoza 27-28 April 2017
Presentation in the framework of the International Conference "10th anniversary of the Spanish Network of Health Technology Assessment Agencies. Towads patient and public engagement in HTA" Zaragoza 27-28 April 2017
Presentation in the framework of the International Conference "10th anniversary of the Spanish Network of Health Technology Assessment Agencies. Towads patient and public engagement in HTA" Zaragoza 27-28 April 2017
Presentation in the framework of the International Conference "10th anniversary of the Spanish Network of Health Technology Assessment Agencies. Towads patient and public engagement in HTA" Zaragoza 27-28 April 2017
Presentation in the framework of the International Conference "10th anniversary of the Spanish Network of Health Technology Assessment Agencies. Towads patient and public engagement in HTA" Zaragoza 27-28 April 2017
Presentation in the framework of the International Conference "10th anniversary of the Spanish Network of Health Technology Assessment Agencies. Towads patient and public engagement in HTA" Zaragoza 27-28 April 2017
Presentation in the framework of the International Conference "10th anniversary of the Spanish Network of Health Technology Assessment Agencies. Towads patient and public engagement in HTA" Zaragoza 27-28 April 2017
Presentation in the framework of the International Conference "10th anniversary of the Spanish Network of Health Technology Assessment Agencies. Towads patient and public engagement in HTA" Zaragoza 27-28 April 2017
Presentation in the framework of the International Conference "10th anniversary of the Spanish Network of Health Technology Assessment Agencies. Towads patient and public engagement in HTA" Zaragoza 27-28 April 2017
Presentation in the framework of the International Conference "10th anniversary of the Spanish Network of Health Technology Assessment Agencies. Towads patient and public engagement in HTA" Zaragoza 27-28 April 2017
Presentation in the framework of the International Conference "10th anniversary of the Spanish Network of Health Technology Assessment Agencies. Towads patient and public engagement in HTA" Zaragoza 27-28 April 2017
Presentation in the framework of the International Conference "10th anniversary of the Spanish Network of Health Technology Assessment Agencies. Towads patient and public engagement in HTA" Zaragoza 27-28 April 2017
Presentation in the framework of the International Conference "10th anniversary of the Spanish Network of Health Technology Assessment Agencies. Towads patient and public engagement in HTA" Zaragoza 27-28 April 2017
Presentation in the framework of the International Conference "10th anniversary of the Spanish Network of Health Technology Assessment Agencies. Towads patient and public engagement in HTA" Zaragoza 27-28 April 2017
Is there patient involvement in HTA? Can patients influence HTA decision making?Kathi Apostolidis
Is HTA purely technical?
drivers for patient involvement in HTA
patient participation or tokenism
medicines do not reach patients due to delays in HTA evaluation
need for harmonized HTA
The Observatory of Innovation in Healthcare Management in Catalonia is the instrument used by the Catalan health system to catalogue the efforts made by organisations in innovating in several spheres of management. See more information at http://oigs.gencat.cat
Drug development and treatment strategies may go hand in hand.EUPATI
How early in the development of a new medicine should the discussion between researchers and patients occur? Can such early strategic interaction really maximize the value of the outcome? In this EUPATI webinar, a pharmaceutical industry researcher and a patient expert will present two cases describing the research questions, their interaction and the outcome of this early collaboration. Join us in listening and discussing two very interesting experiences of successful patient involvement in the development of new medicines.
A very important result from the EUPATI project was the development, broad consultation and final release of guidances on the best approach to interaction of patients with pharmaceutical industry-led medicines R&D, regulatory authorities, ethics committees and HTA agencies. This webinar focuses on the Patient Involvement in Industry-led R&D guidance document
Shared Decision Making in health (Decisions Compartides) is a project of the Catalan Health Ministry of the Generalitat de Catalunya. Physicians and patients are involved in shared medical decisions. Both parties share information (evidence based information about treatment options, cons and pros, patient preferences and values) and an agreement is reached on the treatment to implement.
Essencial "Adding value to clinical practice" is an initiative which identifies low-value clinical practices and promotes recommendations on how to avoid them.
Tripartite dimension of interaction of patients, regulators and industry (Jan...jangeissler
Tripartite dimension of interaction of patients, regulators and industry, presented by Jan Geissler as a scene-setting presentation at the EUPATI Workshop on the interaction of patients, regulators and industry on 20 July 2016 in Berlin
How to communicate scientific and medical information to patients, advocates ...jangeissler
How to communicate scientific and medical information to patients, advocates and caregivers, presented by Jan Geissler at the European Medical Writer's Symposium (EMWA) on 12 May 2016
Presentation in the framework of the International Conference "10th anniversary of the Spanish Network of Health Technology Assessment Agencies. Towads patient and public engagement in HTA" Zaragoza 27-28 April 2017
Presentation in the framework of the International Conference "10th anniversary of the Spanish Network of Health Technology Assessment Agencies. Towads patient and public engagement in HTA" Zaragoza 27-28 April 2017
Presentation in the framework of the International Conference "10th anniversary of the Spanish Network of Health Technology Assessment Agencies. Towads patient and public engagement in HTA" Zaragoza 27-28 April 2017
Presentation in the framework of the International Conference "10th anniversary of the Spanish Network of Health Technology Assessment Agencies. Towads patient and public engagement in HTA" Zaragoza 27-28 April 2017
Is there patient involvement in HTA? Can patients influence HTA decision making?Kathi Apostolidis
Is HTA purely technical?
drivers for patient involvement in HTA
patient participation or tokenism
medicines do not reach patients due to delays in HTA evaluation
need for harmonized HTA
The Observatory of Innovation in Healthcare Management in Catalonia is the instrument used by the Catalan health system to catalogue the efforts made by organisations in innovating in several spheres of management. See more information at http://oigs.gencat.cat
Drug development and treatment strategies may go hand in hand.EUPATI
How early in the development of a new medicine should the discussion between researchers and patients occur? Can such early strategic interaction really maximize the value of the outcome? In this EUPATI webinar, a pharmaceutical industry researcher and a patient expert will present two cases describing the research questions, their interaction and the outcome of this early collaboration. Join us in listening and discussing two very interesting experiences of successful patient involvement in the development of new medicines.
A very important result from the EUPATI project was the development, broad consultation and final release of guidances on the best approach to interaction of patients with pharmaceutical industry-led medicines R&D, regulatory authorities, ethics committees and HTA agencies. This webinar focuses on the Patient Involvement in Industry-led R&D guidance document
Shared Decision Making in health (Decisions Compartides) is a project of the Catalan Health Ministry of the Generalitat de Catalunya. Physicians and patients are involved in shared medical decisions. Both parties share information (evidence based information about treatment options, cons and pros, patient preferences and values) and an agreement is reached on the treatment to implement.
Essencial "Adding value to clinical practice" is an initiative which identifies low-value clinical practices and promotes recommendations on how to avoid them.
Tripartite dimension of interaction of patients, regulators and industry (Jan...jangeissler
Tripartite dimension of interaction of patients, regulators and industry, presented by Jan Geissler as a scene-setting presentation at the EUPATI Workshop on the interaction of patients, regulators and industry on 20 July 2016 in Berlin
How to communicate scientific and medical information to patients, advocates ...jangeissler
How to communicate scientific and medical information to patients, advocates and caregivers, presented by Jan Geissler at the European Medical Writer's Symposium (EMWA) on 12 May 2016
Structure and development of a clinical decision support system: application ...komalicarol
Clinical decision requires to infer great, diverse and not suitably
organized quantity of information and having low time to decide.
The therapeutic choice is fundamental to formulate a strategy to
avoid complications and to achieve favorable results, being more
important in some specialties. In addition, medical decision-makers are overloaded with clinical tasks, have an intense work rate and
are subject to a great demand, and are prone to greater tiredness.
In this sense, computer tools can be extremely useful, as can deal
with a lot of information in much less time than decision-makers.
Thus, the existence of a tool that assists them in decision-making
is of crucial importance
The Role of Technology in Streamlining Clinical Trial ProcessesClinosolIndia
Technology plays a significant role in streamlining clinical trial processes, enhancing efficiency, data quality, and participant engagement. Here are some key areas where technology contributes to the optimization of clinical trials
10 Ways in which Technology is Driving Better Efficiency in Clinical TrialsInsights10
New technological innovations are improving the efficiency and productivity of clinical trials using novel outcomes, increasing patient engagement, and reducing patient burden. To get a report in detail, contact us at - info@insights10.com
Clinical Trial Registration
International Clinical Trials Registry Platform (ICTRP)
What is the Primary Register?
Clinical Trial Registry - India (CTRI)
Goal and Objectives of the Registry
How to Register?
HXR 2016: Tracking the Body: Devices, Consumer Genomics, and Sensors- Aymen E...HxRefactored
As tracking has become more mainstream, consumers who were once only curious about their heart rate at the gym are now interested in diving deeper and learning more. This session takes a look at the technical side of the latest in telehealth solutions, genomic platforms, and hacks in the world of sensors and devices.
NASSCOM CoE IoT spearheaded a high-level industry roundtable to discuss firsthand the challenges & opportunities in India’s clinical trial industry and how technology can accelerate development
Innovative Hospital Partnership Model for High Quality Patient Clinical TrialsSGS
The biopharmaceutical industry has a growing need for patient trials, even in early phase, to support an early go-no go decision in compound development. Secured access to the patient population, a professional Clinical Pharmacology Unit environment with trained and experienced medical professionals, expertise in early phase project management and clinical operations are key factors for success.
To meet this industry demand, SGS has invested in SGS operated patient units located in hospital partners both in Belgium and Hungary. These centers are also used to build up further cooperation with neighboring early phase sites. SGS staff are involved in the qualification and tailor-made support of sites to achieve SGS quality and operational requirements.
This presentation will present how this partnership model works and why it is so beneficial for all parties.
For more information visit: https://www.sgs.com/exprimo and contact us at: clinicalresearch@sgs.com
Follow us on LinkedIn: https://www.linkedin.com/company/sgs
Big data, RWE and AI in Clinical Trials made simpleHadas Jacoby
Technology is slowly but surely penetrating the healthcare industry in general and the clinical trials sector in particular. New and advanced solutions offer a variety of possibilities aimed to both improving existing processes and creating new and more efficient ones. And on top of all stands the desire to make clinical trials more patient centric.
In all of this, even though some of the technologies have yet to mature enough to meet the high quality standards necessary, it is important to know them and begin imagining the promise they hold for clinical trials.
Intervención de Elisa Puigdomenech Puig (AQuAS) en la III Jornada Red Española de Agencias de Evaluación de Tecnologías Sanitarias y Prestaciones del SNS. Mesa redonda: Grandes retos presentes y futuros
Intervención de Laura Vallejo Torres (SESCS) en la III Jornada Red Española de Agencias de Evaluación de Tecnologías Sanitarias y Prestaciones del SNS. Mesa redonda: Grandes retos presentes y futuros
More from Instituto Aragonés de Ciencias de la Salud - IACS (18)
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
The Importance of Community Nursing Care.pdfAD Healthcare
NDIS and Community 24/7 Nursing Care is a specific type of support that may be provided under the NDIS for individuals with complex medical needs who require ongoing nursing care in a community setting, such as their home or a supported accommodation facility.
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...
Jornadas #PatientInHTA · Jesús González
1. Zaragoza, 27-28 April 2017
How can we build into the system the ability to review decisions
made on the basis of results? Monitoring Technologies for their
inclusion in the Spanish Health System Benefits Basket
Jesús González Enríquez
AETS-ISCIII
PUBLIC HEALTH CONFERENCE
10th anniversary of the Spanish Network of Health Technology Assessment (HTA) Agencies:
Insights for collaborative networking
Towards Patient and public engagement in HTA
2. Coverage with evidence generation. CEG
Heath authority decisions on coverage/funding conditional on the
collection of data on effectiveness and cost-effectiveness (evidence
generation/development), an option when there is uncertainty of net
benefits of a technology.
Experimental or under research within the framework of CCT or
registers.
Research in treatments with few or no alternatives.
Potential benefits still not clearly demonstrated against
alternatives.
Without coverage, it is not possible to generate new relevant
evidence.
3. Coverage with evidence generation. CEG
Assumption of risks making decisions under uncertainty:
Type I error : Covering technologies that are clinically ineffective or
harmful.
Type II error: Denying access to potentially beneficial or cost-
effective technologies.
Specific coverage only in research (for patients involved in the
research).
Temporary post-introduction covering with research (all patients
are given access).
Covering with risk sharing (payment linked to results or
performance, number of patients).
4.
5. Coverage with evidence generation
Technology selection criteria:
Due to diferencies on regulatory approval and access to the
market: Medical devices, diagnostic tecnologies, surgical
procedures and surgical implants.
Expected improvement in health benefits but still not clearly
shown comparing with rutine effective alternatives.
Potential impact for widespread and risks with little evidence.
6. Coverage with evidence generation
Technology selection criteria:
Required regulatory approval.
Insufficient evidence to answer key questions.
In the absence of CEG evidence would not become available.
Feasibility/usefulness of the study design (value of new evidence)
The benefits of generating additional evidence justify costs,
resources and time.
Time framework for decision adapted to technology life- cycle.
7. Potential Advantages and Disadvantages associated with CEG
Advantages Disadvantages
Decision makers Managed entry of
promising tech. Evidence
generation.
Investment in tech. that
prove not to be CE.
Additional costs of
monitoring, difficulty in
withdrawing tech.
Healthcare Providers Earlier access to promising
tech.
Risks using tech. not fully
evaluated.
Manufacturers Initial adoption of tech.
with equivocal evidence.
Delays to market access for
effective tech. Additional
burden of monitoring.
Patients Access to promising tech.
otherwise not available.
Access to tech. that may
prove to be ineffective or
unsafe.
8.
9. *Prior pilots of CEG (2000-2015)
*Positron Emission Tomography (PET) in Oncology
*Surgery for epilepsy
*Chondrocyte transplantation
*Stent for Abdominal Aortic Aneurysm
*Artificial Anal Sphincter in Severe Fecal Incontinence
*Neurosurgical treatment for Parkinson
*Intracoronary brachitherapy
Pre - introduction coverage:
*Surgical treatment for HIV-related facial lipoatrophy
10. Monitoring studies
Concept (MoH order 1356 / 2015, 2 July)
Registers for the assessment of health interventions and
techniques (implants) in phase of post-introduction in
benefits basket when:
There is uncertainty about its effectiveness or its
efficiency in clinical practice.
Unknown effects in specific population groups.
Expected high economic or organizational impact.
11. *Monitoring studies
Features
Technical coordination by an agency of HTA (Spanish Network of
HTA Agencies).
Application only in health centers designated by the autonomous
communities on the basis of the Protocol.
Access to all users of the NHS that comply with the Protocol.
Final report to Health Authority to inform on the inclusion,
exclusion or modification of use in the benefits basket.
12. *Monitoring studies
Objectives
To collect and analyze data that allow you to provide
relevant new information to:
Inform on the inclusion of the technologies in the
benefits basket of services under the current
conditions of use or
modify its conditions of use, or their exclusion
Order by the MoH
13. Data registry
13
Monitoring studies
MS Specific
requirements
CCAA
DECISION
A
G
E
N
C
Y
H
T
A
Health
centers
Protocol
•Inclusion
•Exclusion
•Modify
Final
report
CPAF
Benefits
Basket
Commission
MoH order
Decision of
MoH
CISNS
14. * The agencies of HTA are responsible for
Technical coordination
Coordinating the protocol consensus process
Defining the duration of the study
Defining the criteria for inclusion and exclusion of patients
and the variables and outcomes in the MS
Collecting and analyzing the data
Monitoring and quality control of data
Reporting serious adverse effects occurred during the study
Drawing up the final report
15. *MS AGENCIES
Biodegradable stents for the treatment of
refractory or recurrent benign esophageal
stenosis
AETS-ISCIII
Reduction of persistent air leak with
endobronchial valve implants
SECS
Percutaneous mitral valve repair with
MitraClip for severe symptomatic
mitral regurgitation and heart failure
OSTEBA
Percutaneous left atrial appendage
closure device in patients with atrial
fibrillation
AETS-ISCIII
16. * Monitoring Studies main characteristics
Objectives Size Follow-up Study
duration
Device Company
Esophageal
stent
Safety
Effectiveness
130 1 year 36 m SX-ELLA BiOMED SA
Endobronquial
valve
Safety
Effectiveness
Costs
40 1 year 24 m Zephyr
IBV
Assut Europe
Olimpus
Mitra Clip Safety and
Efectiveness
Cost-
effectiveness
140 1 year 26 m MitraClip ABBOT
Left Atrial
Appendage
closure
Safety
Effectiveness
150 2 years 48 m Watchman
Amplatzer
LAA Ultraseal
Lambre
Boston Sc
St Jude Med
Mercé V
Evomed SL
17. *MS protocol elaboration
Elaboration of the first part of the protocols (tech
description, evidence, requirements, objectives).
Consensus process meetings (clinical experts, MoH,
Spanish Agency of Medicinal Products and Medical
Devices, agencies).
Protocol draft (inclusion/exclusion criteria, variables,
outcomes, follow-up periods, sample size, analysis,
model for informed consent).
18. *MS protocol elaboration
Other characteristics of the study methodology.
Characteristics and requirements of the centers to
participate in the study (expertise, clinical training,
resources).
Reviewed by other designated clinical experts,
companies. involved, and members of the Benefits
Basket Commission (CPAF).
Protocol final approval.
19. *SIEM
The MoH has developed a web based tool to record information
from each monitoring study (Information System of Monitoring
Studies (SIEM).
User manuals for the coordinating agency and for other users have
been developed (secure access, working with the tool, designing
formularies, statistics).
The agencies design the specific protocol database using SIEM.
Authorized clinician at each participating center load the data of
the intervened patients.
The information is finally analyzed by the agency.
20. *Current situation
All final MS protocols have been approved.
Designation by the autonomous regions of the centers
participating in the MS (requirements, authorizations,
signature for adhesion, self-assessment questionnaire,
conflict of interest). 27 Hospital centers in 12
autonomous regions.
Information System of Monitoring Studies (SIEM) is
already operational.
Specific protocol databases design using the tool (SIEM)
completed.
MS in the phase of inclusion of patients.
21. *Discussion
MS is an option for decisions on coverage/funding
conditional on evidence generation when there is
uncertainty of net benefits of a technology.
We need a clear procedure of identification, selection
and prioritisation of technologies suitable for MS.
We have made progress in standardization of
procedures (protocol consensus, handling conflicts of
interest, process of designation of centers).
We need to define the role of companies with interest
in the process.
Adaptation of long technology cycle and the decision
of coverage with additional evidence.